Lista de obras - Frank S. Menniti - Dominio Público Uruguay

(3R,4S)-3-[4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl]chroman-4,7-diol: a conformationally restricted analogue of the NR2B subtype-selective NMDA antagonist (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)- 1-propanol

artículo científico publicado en 1998

1-Aryl-6,7-methylenedioxy-3 H -quinazolin-4-ones as anticonvulsant agents

artículo científico publicado en 2003

A non-brain penetrant PDE5A inhibitor improves functional recovery after stroke in rats

artículo científico publicado en 2012

Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A.

artículo científico publicado en 2009

An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

artículo científico publicado en 2008

Antinociceptive activity of CP‐101,606, an NMDA receptor NR2B subunit antagonist ⬇️

artículo científico publicado el 1 de noviembre de 1997

Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors.

artículo científico publicado en 2000

Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys

scientific article published on 13 July 2007

CP-101,606, a potent neuroprotectant selective for forebrain neurons

artículo científico publicado en 1997

CP-101,606, an NR2B subunit selective NMDA receptor antagonist, inhibits NMDA and injury induced c-fos expression and cortical spreading depression in rodents

scientific article published on 01 April 2000

CP-465,022, a selective noncompetitive AMPA receptor antagonist, blocks AMPA receptors but is not neuroprotective in vivo

artículo científico publicado en 2003

Characterization of the mechanism of anticonvulsant activity for a selected set of putative AMPA receptor antagonists

artículo científico publicado en 2003

Differential Effects of an NR2B NAM and Ketamine on Synaptic Potentiation and Gamma Synchrony: Relevance to Rapid-Onset Antidepressant Efficacy

artículo científico publicado en 2015

Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease

artículo científico publicado en 2004

Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia

artículo científico publicado en 2009

Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors

artículo científico publicado en 2007

Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.

artículo científico publicado en 2008

Functional characterization of CP-465,022, a selective, noncompetitive AMPA receptor antagonist

artículo científico publicado en 2002

Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function.

artículo científico publicado en 2006

Glutamate receptor ion channels: structure, regulation, and function

artículo científico publicado en 2010

Immunohistochemical localization of PDE10A in the rat brain

scientific journal article

Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species

artículo científico publicado en 2006

Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical Stimulation

artículo científico publicado en 2009

Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease

artículo científico publicado en 2010

Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.

artículo científico publicado en 2006

MPX-004 and MPX-007: New Pharmacological Tools to Study the Physiology of NMDA Receptors Containing the GluN2A Subunit

artículo científico publicado en 2016

Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct

artículo científico publicado en 2009

Methaqualone derivatives are potent noncompetitive AMPA receptor antagonists

artículo científico publicado en 2000

Molecular mechanism of AMPA receptor noncompetitive antagonism

artículo científico publicado en 2005

NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats

artículo científico publicado en 2004

New 7,8-ethylenedioxy-2,3-benzodiazepines as noncompetitive AMPA receptor antagonists

artículo científico publicado en 2005

PDE inhibition and cognition enhancement

artículo científico publicado en 2012

PTC-174, a positive allosteric modulator of NMDA receptors containing GluN2C or GluN2D subunits

scientific article published on 25 January 2020

Persistence of dihydrotestosterone inhibition of lordosis in estrogen-primed rats fed a tryptophan-deficient diet

scientific article published on 01 July 1981

Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease

artículo científico publicado en 2009

Phosphodiesterase 10A inhibitor MP-10 effects in primates: comparison with risperidone and mechanistic implications

artículo científico publicado en 2014

Phosphodiesterase 5A inhibitors improve functional recovery after stroke in rats: optimized dosing regimen with implications for mechanism

artículo científico publicado en 2009

Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo

artículo científico publicado en 2012

Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: indications for central and peripheral mechanisms

artículo científico publicado en 2012

Phosphodiesterases in the CNS: targets for drug development

artículo científico publicado en 2006

Positive allosteric modulation of AMPA receptors from efficacy to toxicity: the interspecies exposure-response continuum of the novel potentiator PF-4778574.

artículo científico publicado en 2013

Potent and cellularly active 4-aminoimidazole inhibitors of cyclin-dependent kinase 5/p25 for the treatment of Alzheimer's disease

artículo científico publicado en 2009

Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms

artículo científico publicado en 2003

Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction

artículo científico publicado en 2010

Quantification of MPTP-induced dopaminergic neurodegeneration in the mouse substantia nigra by laser capture microdissection

artículo científico publicado en 2006

Quinazolin-4-one alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists: structure-activity relationship of the C-2 side chain tether

artículo científico publicado en 2001

Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice

artículo científico publicado en 2003

Role of estrogen receptors in neuroprotection by estradiol against MPTP toxicity

artículo científico publicado en 2007

Structural basis for the catalytic mechanism of human phosphodiesterase 9

artículo científico publicado en 2008

Synthesis of 2-semicarbazonomethyl-4,5-methylenedioxyphenylacetic acids as anticonvulsant agents

artículo científico publicado en 2005

Synthesis of novel pyrrolo[3,4-d]pyrazole-dicarboxylic acids and evaluation of their interaction with glutamate receptors

artículo científico publicado en 2008

Synthesis, chiral resolution, and enantiopharmacology of a potent 2,3-benzodiazepine derivative as noncompetitive AMPA receptor antagonist.

artículo científico publicado en 2006

The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.

artículo científico publicado en 2004

The distribution of phosphodiesterase 2A in the rat brain.

artículo científico publicado en 2012

The phencyclidine-like discriminative stimulus effects and reinforcing properties of the NR2B-selective N-methyl-D-aspartate antagonist CP-101 606 in rats and rhesus monkeys.

artículo científico publicado en 2007

Translational psychiatry--light at the end of the tunnel.

artículo científico publicado en 2015

Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia

artículo científico publicado en 2011

Lista de obras de Frank S. Menniti

(3R,4S)-3-[4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl]chroman-4,7-diol: a conformationally restricted analogue of the NR2B subtype-selective NMDA antagonist (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)- 1-propanol

1-Aryl-6,7-methylenedioxy-3 H -quinazolin-4-ones as anticonvulsant agents

A non-brain penetrant PDE5A inhibitor improves functional recovery after stroke in rats

Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A.

An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

Antinociceptive activity of CP‐101,606, an NMDA receptor NR2B subunit antagonist ⬇️

Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors.

Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys

CP-101,606, a potent neuroprotectant selective for forebrain neurons

CP-101,606, an NR2B subunit selective NMDA receptor antagonist, inhibits NMDA and injury induced c-fos expression and cortical spreading depression in rodents

CP-465,022, a selective noncompetitive AMPA receptor antagonist, blocks AMPA receptors but is not neuroprotective in vivo

Characterization of the mechanism of anticonvulsant activity for a selected set of putative AMPA receptor antagonists

Differential Effects of an NR2B NAM and Ketamine on Synaptic Potentiation and Gamma Synchrony: Relevance to Rapid-Onset Antidepressant Efficacy

Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease

Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia

Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors

Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.

Functional characterization of CP-465,022, a selective, noncompetitive AMPA receptor antagonist

Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function.

Glutamate receptor ion channels: structure, regulation, and function

Immunohistochemical localization of PDE10A in the rat brain

Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species

Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical Stimulation

Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease

Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.

MPX-004 and MPX-007: New Pharmacological Tools to Study the Physiology of NMDA Receptors Containing the GluN2A Subunit

Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct

Methaqualone derivatives are potent noncompetitive AMPA receptor antagonists

Molecular mechanism of AMPA receptor noncompetitive antagonism

NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats

New 7,8-ethylenedioxy-2,3-benzodiazepines as noncompetitive AMPA receptor antagonists

PDE inhibition and cognition enhancement

PTC-174, a positive allosteric modulator of NMDA receptors containing GluN2C or GluN2D subunits

Persistence of dihydrotestosterone inhibition of lordosis in estrogen-primed rats fed a tryptophan-deficient diet

Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease

Phosphodiesterase 10A inhibitor MP-10 effects in primates: comparison with risperidone and mechanistic implications

Phosphodiesterase 5A inhibitors improve functional recovery after stroke in rats: optimized dosing regimen with implications for mechanism

Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo

Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: indications for central and peripheral mechanisms

Phosphodiesterases in the CNS: targets for drug development

Positive allosteric modulation of AMPA receptors from efficacy to toxicity: the interspecies exposure-response continuum of the novel potentiator PF-4778574.

Potent and cellularly active 4-aminoimidazole inhibitors of cyclin-dependent kinase 5/p25 for the treatment of Alzheimer's disease

Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms

Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction

Quantification of MPTP-induced dopaminergic neurodegeneration in the mouse substantia nigra by laser capture microdissection

Quinazolin-4-one alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists: structure-activity relationship of the C-2 side chain tether

Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice

Role of estrogen receptors in neuroprotection by estradiol against MPTP toxicity

Structural basis for the catalytic mechanism of human phosphodiesterase 9

Synthesis of 2-semicarbazonomethyl-4,5-methylenedioxyphenylacetic acids as anticonvulsant agents

Synthesis of novel pyrrolo[3,4-d]pyrazole-dicarboxylic acids and evaluation of their interaction with glutamate receptors

Synthesis, chiral resolution, and enantiopharmacology of a potent 2,3-benzodiazepine derivative as noncompetitive AMPA receptor antagonist.

The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.

The distribution of phosphodiesterase 2A in the rat brain.

The phencyclidine-like discriminative stimulus effects and reinforcing properties of the NR2B-selective N-methyl-D-aspartate antagonist CP-101 606 in rats and rhesus monkeys.

Translational psychiatry--light at the end of the tunnel.

Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia